Related Experiment Video
Updated: Jan 17, 2026
Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
Published on: December 1, 2023
Feasibility of Subcutaneous Immunoglobulin Therapy as the Maintenance Therapy in Patients with Autoimmune
Faraz S Hussain1, Zaeem A Siddiqi1
1Division of Neurology, Department of Medicine, Faculty of Medicine and Dentistry, University of Albertahttps://ror.org/0160cpw27, Edmonton, Canada.
Long-term immunoglobulin therapy is crucial for several neuromuscular disorders (NMD). Recently, subcutaneous immunoglobulin (SCIg) has become an alternate to intravenous immunoglobulin (IVIg) for maintenance therapy to address limitations. This prospective study assessed the feasibility of SCIg as maintenance therapy for various NMDs after transitioning from IVIg. Overall, the mean monthly immunoglobulin dose remained stable or reduced after transition while maintaining efficacy. Participants reported significantly fewer side effects (29.2 % vs. 66.7%) with SCIg. Compliance with self-infusion and dosing regimen with SCIg was high, with no product wastage. The study shows SCIg therapy has distinct advantages over IVIg and should be considered for NMD patients requiring maintenance therapy.
Long-term immunoglobulin therapy is crucial for several neuromuscular disorders (NMD). Recently, subcutaneous immunoglobulin (SCIg) has become an alternate to intravenous immunoglobulin (IVIg) for maintenance therapy to address limitations. This prospective study assessed the feasibility of SCIg as maintenance therapy for various NMDs after transitioning from IVIg. Overall, the mean monthly immunoglobulin dose remained stable or reduced after transition while maintaining efficacy. Participants reported significantly fewer side effects (29.2 % vs. 66.7%) with SCIg. Compliance with self-infusion and dosing regimen with SCIg was high, with no product wastage. The study shows SCIg therapy has distinct advantages over IVIg and should be considered for NMD patients requiring maintenance therapy.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
01:15Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...